On Tuesday, 4D Molecular Therapeutics Inc (NASDAQ: FDMT) was 5.52% up from the session before settling in for the closing price of $3.89. A 52-week range for FDMT has been $3.84 – $36.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 101.44% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -18.70%. With a float of $39.63 million, this company’s outstanding shares have now reached $45.79 million.
In an organization with 227 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 100.0%, operating margin of -507678.38%, and the pretax margin is -434778.38%.
4D Molecular Therapeutics Inc (FDMT) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward 4D Molecular Therapeutics Inc stocks. The insider ownership of 4D Molecular Therapeutics Inc is 14.40%, while institutional ownership is 92.16%. The most recent insider transaction that took place on Sep 16 ’24, was worth 8,165. In this transaction Chief Legal Officer of this company sold 500 shares at a rate of $16.33, taking the stock ownership to the 6,781 shares. Before that another transaction happened on Aug 19 ’24, when Company’s Chief Legal Officer sold 500 for $15.00, making the entire transaction worth $7,500. This insider now owns 6,781 shares in total.
4D Molecular Therapeutics Inc (FDMT) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.89 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -18.70% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -4.47% during the next five years compared to -9.89% drop over the previous five years of trading.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Trading Performance Indicators
You can see what 4D Molecular Therapeutics Inc (FDMT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 14.92. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4757.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.16, a number that is poised to hit -0.86 in the next quarter and is forecasted to reach -3.84 in one year’s time.
Technical Analysis of 4D Molecular Therapeutics Inc (FDMT)
Let’s dig in a bit further. During the last 5-days, its volume was 0.83 million. That was inferior than the volume of 0.84 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 18.32%. Additionally, its Average True Range was 0.39.
During the past 100 days, 4D Molecular Therapeutics Inc’s (FDMT) raw stochastic average was set at 7.03%, which indicates a significant decrease from 33.73% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 66.33% in the past 14 days, which was lower than the 75.56% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.02, while its 200-day Moving Average is $12.04. However, in the short run, 4D Molecular Therapeutics Inc’s stock first resistance to watch stands at $4.27. Second resistance stands at $4.44. The third major resistance level sits at $4.71. If the price goes on to break the first support level at $3.84, it is likely to go to the next support level at $3.56. The third support level lies at $3.40 if the price breaches the second support level.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Key Stats
There are 46,302K outstanding shares of the company, which has a market capitalization of 190.30 million. As of now, sales total 40 K while income totals -160,870 K. Its latest quarter income was 0 K while its last quarter net income were -43,840 K.
